NAGE vs. ZLAB, PTCT, RARE, MRUS, ACLX, ACAD, SWTX, RNA, AAPG, and SRRK
Should you be buying Niagen Bioscience stock or one of its competitors? The main competitors of Niagen Bioscience include Zai Lab (ZLAB), PTC Therapeutics (PTCT), Ultragenyx Pharmaceutical (RARE), Merus (MRUS), Arcellx (ACLX), ACADIA Pharmaceuticals (ACAD), SpringWorks Therapeutics (SWTX), Avidity Biosciences (RNA), Ascentage Pharma Group International (AAPG), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry.
Niagen Bioscience vs. Its Competitors
Niagen Bioscience (NASDAQ:NAGE) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.
In the previous week, Niagen Bioscience had 2 more articles in the media than Zai Lab. MarketBeat recorded 6 mentions for Niagen Bioscience and 4 mentions for Zai Lab. Zai Lab's average media sentiment score of 1.26 beat Niagen Bioscience's score of 0.52 indicating that Zai Lab is being referred to more favorably in the news media.
15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 9.4% of Niagen Bioscience shares are held by insiders. Comparatively, 5.0% of Zai Lab shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Niagen Bioscience has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.
Niagen Bioscience has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500. Comparatively, Zai Lab has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500.
Niagen Bioscience currently has a consensus target price of $13.22, indicating a potential upside of 19.64%. Zai Lab has a consensus target price of $54.28, indicating a potential upside of 55.58%. Given Zai Lab's higher probable upside, analysts clearly believe Zai Lab is more favorable than Niagen Bioscience.
Niagen Bioscience has a net margin of 13.07% compared to Zai Lab's net margin of -60.26%. Niagen Bioscience's return on equity of 19.06% beat Zai Lab's return on equity.
Summary
Niagen Bioscience beats Zai Lab on 11 of the 16 factors compared between the two stocks.
Get Niagen Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAGE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Niagen Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:NAGE) was last updated on 7/15/2025 by MarketBeat.com Staff
Free NAGE Stock Alerts